Walgreen, Kroger, Safeway, SuperValu, and HEB have sued Pfizer and Ranbaxy, accusing the drug manufacturers of conspiring to delay generic versions of Lipitor (atorvastatin). Pfizer markets Lipitor and Ranbaxy manufactures the generic version.
The conspiracy allegedy called for a fraudulent patent, sham litigation, a pay-for-delay agreement, and agreements with pharmacy benefit managers requiring them to buy more Lipitor. The retailers claim that these actions kept Lipitor off the market 20 months past the expiration of the original patent.
Lipitor is used to lower cholesterol. It is the best-selling drug in pharmaceutical history.
Full content: Reuters
Related content: Federal Trade Commission Suffers Another Setback in Its Campaign to End Pharmaceutical Reverse-Settlement Agreements
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Justice Department Moves to End NCAA Transfer Rule
May 30, 2024 by
CPI
Kenya’s Competition Authority Proposes Tougher Regulations on Big Tech
May 30, 2024 by
CPI
KKR Secures EU Antitrust Approval for $24 Billion Acquisition of Telecom Italia’s Fixed-Line Network
May 30, 2024 by
CPI
European Court Sides with Tech Giants in Italian Regulatory Dispute
May 30, 2024 by
CPI
US Steel and Nippon Steel Secure International Approvals for $14.9B Merger
May 30, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI